85 related articles for article (PubMed ID: 11259459)
1. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.
Kubo A; Kaye FJ
J Natl Cancer Inst; 2001 Mar; 93(6):415-7. PubMed ID: 11259459
[No Abstract] [Full Text] [Related]
2. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Soni R; O'Reilly T; Furet P; Muller L; Stephan C; Zumstein-Mecker S; Fretz H; Fabbro D; Chaudhuri B
J Natl Cancer Inst; 2001 Mar; 93(6):436-46. PubMed ID: 11259469
[TBL] [Abstract][Full Text] [Related]
3. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
4. Regulation and function of the cyclin-dependent kinase inhibitor p16CDKN2.
Peters G; Parry D; Hara E; Hall M; Bates S; Palmero I
Leukemia; 1997 Apr; 11 Suppl 3():352-5. PubMed ID: 9209387
[TBL] [Abstract][Full Text] [Related]
5. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
6. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
8. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM; Lahusen T
Methods Mol Med; 2003; 85():39-48. PubMed ID: 12710195
[No Abstract] [Full Text] [Related]
9. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.
Ryu CK; Kang HY; Lee SK; Nam KA; Hong CY; Ko WG; Lee BH
Bioorg Med Chem Lett; 2000 Mar; 10(5):461-4. PubMed ID: 10743948
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Beattie JF; Breault GA; Ellston RP; Green S; Jewsbury PJ; Midgley CJ; Naven RT; Minshull CA; Pauptit RA; Tucker JA; Pease JE
Bioorg Med Chem Lett; 2003 Sep; 13(18):2955-60. PubMed ID: 12941311
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel inhibitors of cyclin-dependent kinases.
Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
13. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.
Giocanti N; Sadri R; Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Favaudon V
Ann N Y Acad Sci; 1999; 886():180-2. PubMed ID: 10667214
[No Abstract] [Full Text] [Related]
15. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
16. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Breault GA; Ellston RP; Green S; James SR; Jewsbury PJ; Midgley CJ; Pauptit RA; Minshull CA; Tucker JA; Pease JE
Bioorg Med Chem Lett; 2003 Sep; 13(18):2961-6. PubMed ID: 12941312
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
20. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
